Depending on the national market characteristics and the methodology and source of information used by the associations reporting the data, it may be observed that sales figures for non-prescription medicines or the self-medication market are not available or not possible to estimate.

Figures are presented at the price level at which they were reported by the countries. Sales figures are presented at consumer price level, unless otherwise noted. Presentation at a price level different than consumer price means that available information did not allow the estimation of the market at this price level.

“Non-prescription medicines market” represents the total sales of medicines with a non-prescription status/legal classification.

“Self-medication market” represents the sales of non-prescription medicines purchased directly by consumers without the use of a medical prescription.

Sales figures from European markets are collected mainly in collaboration with member associations of AESGP, IMS Health and national authorities.

For assistance, please contact info@aesgp.eu.

We don’t offer trial period / trial access to the AESGP Data Banks. Detailed information on the content of each AESGP data bank can be found on their respective pages.

Information presented in the databases is based on data provided mainly by AESGP and GSCF member associations. It is reviewed and updated annually.

No, it is not. Upon expiration of your access, you will receive a reminder email inviting you to renew or cancel your subscription.

The subscription is for a period of 12 months (independent the starting date). After this period, you will receive a reminder email inviting you to renew or cancel your subscription.

For more information on partnership fees, please contact us.

You can apply for partnership if you offer, or could offer, services to AESGP or its members in the areas such as advertising, PR, regulatory affairs, marketing, sales and distribution, etc. and if you commit to AESGP mission.

Companies wishing to apply for partnership shall apply in writing to AESGP giving the following information:

• A letter stating that the company wants to join AESGP
• The letter shall be addressed to AESGP President
• The letter shall state your company’s objectives, in particular in the area of self-care

The application will be reviewed by the AESGP board at their next meeting.

For more information on membership fees, please contact us.

If you are not eligible for Full Membership, you can apply to be an Associate Member if you are:

• A national association located in Europe and representing self-care medical devices and/or food supplements, unless one of those categories is already represented by a Full Member.
• A manufacturer of proprietary non-prescription medicines and/or food supplements and/or self-care medical devices in Europe, and are in membership of national associations that are Full or Associate Members in all the countries in which they are present.

You can apply to be a Full Member if you are:

• A national association located in Europe and representing consumer healthcare products manufacturers. Only one association per country is allowed.
• A manufacturer of proprietary non-prescription medicines that meets the following requirements:
  • You are present in a majority of European countries by placing your products on the market,
  • and you are in the membership of all the national associations in Full Membership of AESGP in those countries where you are present. Presence on the market is understood as having an affiliate active in a country.

Associations or companies wishing to apply for Full or Associate membership shall apply in writing to AESGP giving the following information:

• A letter stating that the association/company wants to join AESGP
• The letter shall be addressed to AESGP President
• If you are a company, it is advisable to state your company’s objectives, in particular in the area of self-care, as well as to mention its brand portfolio.
• If you are a national association, it is advisable to state your objectives and the estimated number of members

The application will be reviewed by the AESGP board at their next meeting.

Regulation 2017/745 is applicable since May 2021. Since that date, all medical devices, including self-care medical devices, must comply with the provisions of the Regulation. However, subject to certain conditions, transitional periods allow medical devices with a certificate obtained under the previous legislative framework to be placed on the market at the latest until December 2027 or 2028, depending on the risk class of the given device.

Apart from general changes that affect all types of medical devices, such as improved transparency through a comprehensive EU database on medical devices and a device traceability system based on unique device identification or strengthening of post-market surveillance requirements for manufacturers, Regulation 2017/745 expressly recognizes substance-based medical devices. In particular, classification rule 21 addresses specifically medical devices composed of substances or of combinations of substances.

The main difference between self-care medical devices and (non-prescription) medicines concerns the mode of action. Self-care medical devices achieve their principal intended action by chemico-physical means whereas (non-prescription) medicines act by pharmacological, immunological or metabolic means.